User Guide
Why can I only view 3 results?
You can also view all results when you are connected from the network of member institutions only. For non-member institutions, we are opening a 1-month free trial version if institution officials apply.
So many results that aren't mine?
References in many bibliographies are sometimes referred to as "Surname, I", so the citations of academics whose Surname and initials are the same may occasionally interfere. This problem is often the case with citation indexes all over the world.
How can I see only citations to my article?
After searching the name of your article, you can see the references to the article you selected as soon as you click on the details section.
 Views 29
 Downloands 5
The Outcome of Intravitreal Ranibizumab Injection for Branch Retinal Vein Occlusion Related Macular Edema
2015
Journal:  
European Journal of General Medicine
Author:  
Abstract:

Branch retinal vein occlusion related macular edema (BRVO-ME) is the leading cause of visual loss in patients with Branch retinal vein occlusion (BRVO). In the current study, our aim was to investigate the outcome of intravitreal ranibizumab injection for BRVO-ME. The medical records of randomised thirteen eyes of thirteen patients (7 women and 6 men) with BRVO-ME were reviewed retrospectively. Three and 10 eyes had inferior temporal and superior temporal branch retinal vein occlusion-related macular edema, respectively. At the enrollment visit, all patients received a complete ophthalmic examination, including central subfield (CSF) thickness and average cube thickness measurements using spectral-domain optical coherence tomography (SD-OCT), best corrected visual acuity (BCVA) and intraocular pressure (IOP) measurements. The median patient age was 53 years (range, 38-74). Of the patients, median CSF thickness was 453 μ (range, 221-907), median average cube thickness was 293 μ (range, 237-433), median BCVA was 0.30 logMAR unit (range, 0.05-1.00 logMAR unit), and median IOP scores was 18 mmHg (range, 15-25) at baseline. Compared with baseline, a statistical significance in median CSF thickness scores at week 1 (p=0.015), months 1 (p=0.015), 2 (p=0.030), and 3 (p=0.045) was noted. Compared with baseline, a statistical significance in median BCVA scores at months 2 (p=0.045), 3 (p=0.030), and 6 (p=0.045) was noted. Compared with baseline, no statistical significance in median IOP scores and median average cube thickness scores at week 1, months 1, 2, 3, and 6 was noted (p>0.05, for all). No statistical significance in median CSF thickness scores, median BCVA scores, median IOP scores, or median average cube thickness scores was noted between the other follow-up periods. No complication related to ranibizumab injections was detected during the follow-up period. The treatment method does not cause any increase in IOP score. Besides ranibizumab injection can cause a dramatic decrease in CSF thickness scores and a dramatic increase in BCVA scores as early as at week 1 postoperatively.

Keywords:

Citation Owners
Information: There is no ciation to this publication.
Similar Articles












European Journal of General Medicine

Field :   Sağlık Bilimleri

Journal Type :   Uluslararası

Metrics
Article : 1.230
Cite : 467
2023 Impact : 0.007
European Journal of General Medicine